-
Something wrong with this record ?
PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia
J. Beute, P. Boermans, B. Benraad, J. Telman, Z. Diamant, A. KleinJan
Language English Country Great Britain
Document type Case Reports, Journal Article
NLK
Medline Complete (EBSCOhost)
from 1999-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1980
- MeSH
- COVID-19 MeSH
- Enoximone therapeutic use MeSH
- COVID-19 Drug Treatment MeSH
- Phosphodiesterase 3 Inhibitors therapeutic use MeSH
- Intensive Care Units MeSH
- Middle Aged MeSH
- Humans MeSH
- Respiratory Insufficiency therapy MeSH
- SARS-CoV-2 * MeSH
- Aged MeSH
- Respiration, Artificial * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
BACKGROUND: Standard care in severe SARS-CoV-2 pneumonia complicated by severe dyspnea and respiratory failure, consists of symptom reduction, ultimately supported by mechanical ventilation. Patients with severe SARS-CoV-2, a prominent feature of COVID-19, show several similar symptoms to Critical Asthma Syndrome (CAS) patients, such as pulmonary edema, mucus plugging of distal airways, decreased tissue oxygenation, (emergent) exhaustion due to severe dyspnea and respiratory failure. Prior application of elective phosphodiesterase (PDE)3-inhibitors milrinone and enoximone in patients with CAS yielded rapid symptomatic relief and reverted the need for mechanical ventilation, due to their bronchodilator and anti-inflammatory properties. Based on these observations, we hypothesized that enoximone may be beneficial in the treatment of patients with severe SARS-CoV-2 pneumonia and prominent CAS-features. METHODS: In this case report enoximone was administered to four consecutive patients (1 M; 3 F; 46-70 y) with emergent respiratory failure due to SARS-CoV-2 pneumonia. Clinical outcome was compared with three controls who received standard care only. RESULTS: After an intravenous bolus of enoximone 20 mg followed by 10 mg/h via perfusor, a rapid symptomatic relief was observed: two out of four patients recovered within a few hours, the other two (with comorbid COPD GOLD II/III) responded within 24-36 h. Compared to the controls, in the enoximone-treated patients respiratory failure and further COVID-19-related deterioration was reverted and mechanical ventilation was prevented, leading to reduced hospital/ICU time. DISCUSSION: Our preliminary observations suggest that early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia. Our findings warrant further research on the therapeutic potential of PDE3-inhibition, alone or in combination with other anti-COVID-19 strategies.
Consultants in Quantitative Methods Eindhoven Netherlands
Department of Pulmonary Medicine Erasmus Medical Centre Rotterdam The Netherlands
Dept of Clinical Pharmacy and Pharmacology UMCG Groningen The Netherlands
Dept of Respiratory Diseases Thomayer Hospital Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011408
- 003
- CZ-PrNML
- 005
- 20210507102221.0
- 007
- ta
- 008
- 210420s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/01902148.2021.1881189 $2 doi
- 035 __
- $a (PubMed)33544007
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Beute, Jan $u Almere, The Netherlands
- 245 10
- $a PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia / $c J. Beute, P. Boermans, B. Benraad, J. Telman, Z. Diamant, A. KleinJan
- 520 9_
- $a BACKGROUND: Standard care in severe SARS-CoV-2 pneumonia complicated by severe dyspnea and respiratory failure, consists of symptom reduction, ultimately supported by mechanical ventilation. Patients with severe SARS-CoV-2, a prominent feature of COVID-19, show several similar symptoms to Critical Asthma Syndrome (CAS) patients, such as pulmonary edema, mucus plugging of distal airways, decreased tissue oxygenation, (emergent) exhaustion due to severe dyspnea and respiratory failure. Prior application of elective phosphodiesterase (PDE)3-inhibitors milrinone and enoximone in patients with CAS yielded rapid symptomatic relief and reverted the need for mechanical ventilation, due to their bronchodilator and anti-inflammatory properties. Based on these observations, we hypothesized that enoximone may be beneficial in the treatment of patients with severe SARS-CoV-2 pneumonia and prominent CAS-features. METHODS: In this case report enoximone was administered to four consecutive patients (1 M; 3 F; 46-70 y) with emergent respiratory failure due to SARS-CoV-2 pneumonia. Clinical outcome was compared with three controls who received standard care only. RESULTS: After an intravenous bolus of enoximone 20 mg followed by 10 mg/h via perfusor, a rapid symptomatic relief was observed: two out of four patients recovered within a few hours, the other two (with comorbid COPD GOLD II/III) responded within 24-36 h. Compared to the controls, in the enoximone-treated patients respiratory failure and further COVID-19-related deterioration was reverted and mechanical ventilation was prevented, leading to reduced hospital/ICU time. DISCUSSION: Our preliminary observations suggest that early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia. Our findings warrant further research on the therapeutic potential of PDE3-inhibition, alone or in combination with other anti-COVID-19 strategies.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a COVID-19 $7 D000086382
- 650 _2
- $a enoximon $x terapeutické užití $7 D017335
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jednotky intenzivní péče $7 D007362
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a inhibitory fosfodiesterasy 3 $x terapeutické užití $7 D058987
- 650 12
- $a umělé dýchání $7 D012121
- 650 _2
- $a respirační insuficience $x terapie $7 D012131
- 650 12
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Boermans, Pieter $u Rode Kruis Ziekenhuis, Beverwijk, The Netherlands
- 700 1_
- $a Benraad, Bart $u Mbrace Pharma BV, Zeewolde, The Neterlands
- 700 1_
- $a Telman, Jan $u Consultants in Quantitative Methods, Eindhoven, Netherlands
- 700 1_
- $a Diamant, Zuzana $u Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden $u Dept of Clinical Pharmacy & Pharmacology, UMCG, Groningen, The Netherlands $u Dept of Respiratory Diseases, Thomayer Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a KleinJan, Alex $u Department of Pulmonary Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
- 773 0_
- $w MED00001747 $t Experimental lung research $x 1521-0499 $g Roč. 47, č. 3 (2021), s. 149-160
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33544007 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507102220 $b ABA008
- 999 __
- $a ok $b bmc $g 1649947 $s 1131787
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 47 $c 3 $d 149-160 $e 20210205 $i 1521-0499 $m Experimental lung research $n Exp Lung Res $x MED00001747
- LZP __
- $a Pubmed-20210420
